252 related articles for article (PubMed ID: 27161545)
1. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.
Cui Y; Cao W; Li Q; Shen H; Liu C; Deng J; Xu J; Shao Q
Sci Rep; 2016 May; 6():25776. PubMed ID: 27161545
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis.
Xue WJ; Ying XL; Jiang JH; Xu YH
J Cancer Res Ther; 2014 Nov; 10 Suppl():C218-21. PubMed ID: 25450286
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.
Hu B; Yang H; Yang H
Tumour Biol; 2014 Sep; 35(9):8573-80. PubMed ID: 24863945
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.
Qin Z; Yao J; Xu L; Xu Z; Ge Y; Zhou L; Zhao F; Jia R
Int Braz J Urol; 2020; 46(5):691-704. PubMed ID: 31961625
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis.
Luo Y; Gou X; Huang P; Mou C
Chin Med J (Engl); 2014; 127(9):1768-74. PubMed ID: 24791889
[TBL] [Abstract][Full Text] [Related]
6. Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies.
Jiang Z; Zhao Y; Tian Y
Minerva Urol Nefrol; 2019 Aug; 71(4):373-380. PubMed ID: 30203935
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
8. PSAD Test in the Diagnosis of Prostate Cancer: a Meta-Analysis.
Feng ZJ; Xue C; Wen JM; Li Y; Wang M; Zhang N
Clin Lab; 2017 Jan; 63(1):147-155. PubMed ID: 28164507
[TBL] [Abstract][Full Text] [Related]
9. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
10. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
11. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
12. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
13. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis].
Ruiz-Aragón J; Márquez-Peláez S
Actas Urol Esp; 2010 Apr; 34(4):346-55. PubMed ID: 20470697
[TBL] [Abstract][Full Text] [Related]
15. Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
[TBL] [Abstract][Full Text] [Related]
16. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
17. Progensa™ PCA3 test for prostate cancer.
Durand X; Moutereau S; Xylinas E; de la Taille A
Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis.
Lee D; Shim SR; Ahn ST; Oh MM; Moon DG; Park HS; Cheon J; Kim JW
Clin Genitourin Cancer; 2020 Oct; 18(5):402-408.e5. PubMed ID: 32280028
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
20. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
